INTEGRATED BIOPHARMA INC (INBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 25M 50M 75M Q4 '21: 63.6M Q1 '22: 61.1M Q2 '22: 61.5M Q3 '22: 60M Q4 '22: 56.2M Q1 '23: 55.8M Q2 '23: 53.5M Q3 '23: 50.9M Q4 '23: 50.7M Q1 '24: 51.3M Q2 '24: 50.5M Q3 '24: 50.6M Q4 '24: 50.3M Q1 '25: 51M Q2 '25: 52.1M Q3 '25: 52.9M Q4 '25: 54.4M Q1 '26: 53.4M Q2 '26: 52.1M Q3 '26: 48.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit TTM

0 3.5M 7M 10.5M Q4 '21: 9.5M Q1 '22: 8.5M Q2 '22: 8.1M Q3 '22: 7.4M Q4 '22: 6.6M Q1 '23: 6.1M Q2 '23: 5.4M Q3 '23: 4.5M Q4 '23: 4.1M Q1 '24: 3.9M Q2 '24: 3.3M Q3 '24: 3.6M Q4 '24: 3.9M Q1 '25: 4.4M Q2 '25: 5.1M Q3 '25: 5.4M Q4 '25: 5.6M Q1 '26: 5.2M Q2 '26: 4.1M Q3 '26: 2.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income TTM

-2M 0 2M 4M 6M Q4 '21: 5.8M Q1 '22: 4.9M Q2 '22: 4.3M Q3 '22: 3.6M Q4 '22: 2.7M Q1 '23: 2.2M Q2 '23: 1.4M Q3 '23: 479K Q4 '23: 120K Q1 '24: 36K Q2 '24: -383K Q3 '24: -72K Q4 '24: 251K Q1 '25: 795K Q2 '25: 1.4M Q3 '25: 1.8M Q4 '25: 2M Q1 '26: 1.7M Q2 '26: 577K Q3 '26: -1.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-3M 0 3M 6M 9M Q4 '20: 4.1M Q1 '21: 4.8M Q2 '21: 5.1M Q3 '21: 5.4M Q4 '21: 8M Q1 '22: 7.5M Q2 '22: 7.3M Q3 '22: 6.9M Q4 '22: 3.8M Q1 '23: 3.3M Q2 '23: 2.2M Q3 '23: 1.4M Q4 '23: -34K Q1 '24: -58K Q2 '24: -385K Q3 '24: -116K Q4 '24: 112K Q1 '25: 430K Q2 '25: 928K Q3 '25: 1.3M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Cost of Revenue TTM

0 20M 40M 60M Q4 '21: 54.1M Q1 '22: 52.6M Q2 '22: 53.4M Q3 '22: 52.6M Q4 '22: 49.7M Q1 '23: 49.7M Q2 '23: 48M Q3 '23: 46.5M Q4 '23: 46.6M Q1 '24: 47.4M Q2 '24: 47.2M Q3 '24: 47M Q4 '24: 46.4M Q1 '25: 46.6M Q2 '25: 47M Q3 '25: 47.5M Q4 '25: 48.8M Q1 '26: 48.2M Q2 '26: 48M Q3 '26: 46M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow TTM

-2M 0 2M 4M 6M Q4 '21: 3M Q1 '22: 3.2M Q2 '22: 2.6M Q3 '22: 2.1M Q4 '22: 4.1M Q1 '23: 3M Q2 '23: 4.3M Q3 '23: 5.1M Q4 '23: 1.2M Q1 '24: 1.6M Q2 '24: -230K Q3 '24: -57K Q4 '24: 943K Q1 '25: 287K Q2 '25: 2.3M Q3 '25: 1.3M Q4 '25: 2.1M Q1 '26: 2.7M Q2 '26: 3.1M Q3 '26: 3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow TTM

-2M 0 2M 4M 6M Q4 '21: 2.8M Q1 '22: 2.9M Q2 '22: 2.1M Q3 '22: 1.5M Q4 '22: 3.6M Q1 '23: 2.6M Q2 '23: 4.1M Q3 '23: 5M Q4 '23: 1.1M Q1 '24: 1.4M Q2 '24: -326K Q3 '24: -482K Q4 '24: 390K Q1 '25: -284K Q2 '25: 1.7M Q3 '25: 941K Q4 '25: 1.9M Q1 '26: 2.4M Q2 '26: 2.8M Q3 '26: 2.8M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 30.6M Q3 '20: 30.9M Q1 '21: 31.8M Q2 '21: 32.1M Q3 '21: 32.9M Q1 '22: 32.6M Q2 '22: 32.4M Q3 '22: 32.4M Q1 '23: 29.9M Q2 '23: 29.9M Q3 '23: 31.5M Q1 '24: 30M Q2 '24: 30.1M Q3 '24: 30.7M Q1 '25: 30.6M Q2 '25: 31.3M Q3 '25: 31.5M Q1 '26: 31.4M Q2 '26: 31.1M Q3 '26: 31.1M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.09 0.00 0.09 0.18 0.27 Q4 '20: 0.13 Q1 '21: 0.15 Q2 '21: 0.16 Q3 '21: 0.17 Q4 '21: 0.25 Q1 '22: 0.24 Q2 '22: 0.23 Q3 '22: 0.22 Q4 '22: 0.13 Q1 '23: 0.11 Q2 '24: -0.01 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.01 Q2 '25: 0.03 Q3 '25: 0.04 Q4 '25: 0.04 Q1 '26: 0.03 Q2 '26: -0.01 Q3 '26: -0.06 Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.